RxDoctor Payments Data

Kalaivani Sivakumar, MD

Cardiology · Atlanta, GANPI 1548674583

Payments from drug & device makers

What this record shows

This record is dominated by grants: $15,000 of the $16,216 with a category attached, or 92.5%. Medtronic accounts for 92.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2020 at $15,000 and has fallen 98.1% since, to $284 in 2025. Among cardiology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,216in general payments, 2019–2025

Across 18 payments — averaging $900.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$15K
  • Livanova USA, Inc.$384
  • Abbott$222
  • Bridgebio Pharma, Inc.$164
  • Merck$157
  • United Therapeutics Corporation$125
  • plus $164 from 3 others

What the payments were for

  • Grants$15,00093%
  • Food & beverage$1,1397%
  • Education$770%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,216 in reported general payments places this provider in the 95th percentile of 24 cardiology providers in Georgia.

See all cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$122,468
Medicare patients
1,254
Services billed
2,519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis27$970,126
JardianceEmpagliflozin206$231,401
EntrestoSacubitril/Valsartan147$188,921
FarxigaDapagliflozin Propanediol99$91,018
EliquisApixaban52$41,630
Bumetanide120$4,792
Potassium Chloride156$2,668
Digoxin59$1,302
Isosorbide Mononitrate ErIsosorbide Mononitrate79$930
Metoprolol Succinate95$927
Losartan Potassium73$510
Carvedilol60$476
Nifedipine ErNifedipine21$393
Spironolactone43$313
Amiodarone Hcl16$280

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$19$1,011,75779 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 24 cardiology providers in Georgia.

Other cardiology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →